These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 10461848)

  • 1. Estramustine resistance.
    Sangrajrang S; Calvo F; Fellous A
    Gen Pharmacol; 1999 Aug; 33(2):107-13. PubMed ID: 10461848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of estramustine resistance in human prostatic carcinoma cells with modified patterns of tubulin expression.
    Sangrajrang S; Denoulet P; Laing NM; Tatoud R; Millot G; Calvo F; Tew KD; Fellous A
    Biochem Pharmacol; 1998 Feb; 55(3):325-31. PubMed ID: 9484799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estrogen mustard induces cell cycle arrest of human epithelial ovarian cancer cell lines.
    Nathan JD; Keefe DL; Weinstein MA; Chen Z; Naftolin F
    J Soc Gynecol Investig; 1994; 1(1):97-103. PubMed ID: 9419755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estramustine resistance correlates with tau over-expression in human prostatic carcinoma cells.
    Sangrajrang S; Denoulet P; Millot G; Tatoud R; Podgorniak MP; Tew KD; Calvo F; Fellous A
    Int J Cancer; 1998 Aug; 77(4):626-31. PubMed ID: 9679768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance to the antimitotic drug estramustine is distinct from the multidrug resistant phenotype.
    Speicher LA; Sheridan VR; Godwin AK; Tew KD
    Br J Cancer; 1991 Aug; 64(2):267-73. PubMed ID: 1892755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estramustine in malignant glioma.
    Bergenheim AT; Henriksson R; Piepmeier JM; Yoshida D
    J Neurooncol; 1996 Oct; 30(1):81-9. PubMed ID: 8865006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estramustine potentiates taxane in prostate and refractory breast cancers.
    Hamilton A; Muggia F
    Oncology (Williston Park); 2001 May; 15(5 Suppl 7):40-3. PubMed ID: 11396364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estramustine-based chemotherapy.
    Hudes G
    Semin Urol Oncol; 1997 Feb; 15(1):13-9. PubMed ID: 9050135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of estramustine phosphate on the assembly of trypsin-treated microtubules and microtubules reconstituted from purified tubulin with either tau, MAP2, or the tubulin-binding fragment of MAP2.
    Fridén B; Wallin M; Deinum J; Prasad V; Luduena R
    Arch Biochem Biophys; 1987 Aug; 257(1):123-30. PubMed ID: 3115177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increase of beta(III)- and beta(IVa)-tubulin isotopes in human prostate carcinoma cells as a result of estramustine resistance.
    Ranganathan S; Dexter DW; Benetatos CA; Chapman AE; Tew KD; Hudes GR
    Cancer Res; 1996 Jun; 56(11):2584-9. PubMed ID: 8653701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimicrotubule effects of estramustine, an antiprostatic tumor drug.
    Stearns ME; Tew KD
    Cancer Res; 1985 Aug; 45(8):3891-7. PubMed ID: 4016756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined antimicrotubule activity of estramustine and taxol in human prostatic carcinoma cell lines.
    Speicher LA; Barone L; Tew KD
    Cancer Res; 1992 Aug; 52(16):4433-40. PubMed ID: 1353706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estramustine-phosphate binds to a tubulin binding domain on microtubule-associated proteins MAP-2 and tau.
    Moraga D; Rivas-Berrios A; Farías G; Wallin M; Maccioni RB
    Biochim Biophys Acta; 1992 May; 1121(1-2):97-103. PubMed ID: 1599956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism based chemotherapy for prostate cancer.
    Sheridan VR; Tew KD
    Cancer Surv; 1991; 11():239-54. PubMed ID: 1841754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estramustine depolymerizes microtubules by binding to tubulin.
    Dahllöf B; Billström A; Cabral F; Hartley-Asp B
    Cancer Res; 1993 Oct; 53(19):4573-81. PubMed ID: 8402630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of estramustine phosphate in the modern management of advanced prostate cancer.
    Ravery V; Fizazi K; Oudard S; Drouet L; Eymard JC; Culine S; Gravis G; Hennequin C; Zerbib M
    BJU Int; 2011 Dec; 108(11):1782-6. PubMed ID: 21756277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting microtubule-associated proteins in glioblastoma: a new strategy for selective therapy.
    Piepmeier JM; Pedersen PE; Yoshida D; Greer C
    Ann Surg Oncol; 1996 Nov; 3(6):543-9. PubMed ID: 8915486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction of estramustine with tubulin isotypes.
    Laing N; Dahllöf B; Hartley-Asp B; Ranganathan S; Tew KD
    Biochemistry; 1997 Jan; 36(4):871-8. PubMed ID: 9020786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paclitaxel, estramustine, and etoposide in the treatment of hormone-refractory prostate cancer.
    Pienta KJ; Smith DC
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-72-S15-77. PubMed ID: 9346227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cloning and sequencing of human betaIII-tubulin cDNA: induction of betaIII isotype in human prostate carcinoma cells by acute exposure to antimicrotubule agents.
    Ranganathan S; Dexter DW; Benetatos CA; Hudes GR
    Biochim Biophys Acta; 1998 Jan; 1395(2):237-45. PubMed ID: 9473684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.